Deniz Kent

Deniz Kent
Deniz Kent
Born
🏳️ Nationality	Turkish-American
🏫 Education	PhD, King's College London; MSc, King's College London; BSc, University of Bristol
💼 Occupation	Chief Executive Officer, Co-founder
Known for	Co-founding and leading Prolific Machines, pioneering Photomolecular platform
🌐 Website	Prolific Machines

Deniz Kent, PhD is a Turkish-American entrepreneur and the Chief Executive Officer (CEO) and co-founder of Prolific Machines, a biotechnology company using light to bring new innovation to biomanufacturing.

Early Life and Education

Deniz Kent cultivated expertise in biological systems through extensive academic research. He earned his Doctor of Philosophy PhD in the Centre for Stem Cells and Regenerative Medicine at King's College London, where he co-discovered a new human liver stem cell population and conducted the world’s first high throughput small molecule screen using induced pluripotent stem cell iPS-derived hepatocytes.

Prior to his doctoral studies, Kent received his Master of Science Master's degree in biomedical and translational science from King’s College London and his Bachelor of Science Bachelor's degree from the University of Bristol. He also gained early research experience in a cancer immunotherapy lab at the University of Bristol and contributed to research on a single-dose cure for Asthma at GlaxoSmithKline.

Career

Inspired by the burgeoning field of optogenetics, Deniz Kent conceived the idea of using light to elevate biomanufacturing during his PhD studies. He recognized the potential of harnessing light as safe, efficient, and dynamic input to precisely control cellular behavior.

Prolific Machines

In 2020, Deniz Kent co-founded Prolific Machines with Declan Jones and Max Huisman. The Bay Area company is focused on biologics manufacturing with its Photomolecular platform. This light-controlled platform leverages optogenetic tools and closed-loop control software to address protein production challenges across difficult-to-produce protein targets and antibody therapeutics.

To date, Prolific Machines has secured support from leading investors, including Ki Tua Fund (the corporate venture arm of the Fonterra Co-operative Group), Breakthrough Energy Ventures, Mayfield Fund Mayfield, SOSV, and In-Q-Tel, raising approximately $90 million. The company’s vision is to accelerate the future of biology to create a healthier, more sustainable tomorrow by commercially harnessing light to control cellular behavior and optimize this process over time using closed-loop control software.

Kent has expressed his belief that light is the superior way to control biology and eventually, all biomanufacturing will use optogenetics technology.

References

External Links

This article "Deniz Kent" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Deniz Kent. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.